Skip to main content
Full access
Letter to the Editor
Published Online: 1 June 2004

Oxcarbazepine as an Adjunct for Schizophrenia

To the Editor: Despite recent advances, about a quarter of all acutely ill schizophrenic patients still fail to respond to psychopharmacological treatment, even with the newer antipsychotic agents, and side effects remain frequent (1).
The adjunctive administration of anticonvulsant drugs, such as carbamazepine, divalproex, and lamotrigine, has been proposed as a useful treatment strategy for these patients but remains controversial. Under controlled conditions, carbamazepine showed adjunctive effects to antipsychotic treatment (2). The newer anticonvulsant oxcarbazepine represents a prodrug of 10-OH-carbamazepine, the active metabolite of carbamazepine, and shows even better tolerability. So far, it has been investigated only in the treatment of affective disorders.
We report an open-label case series of six male inpatients (mean age=29.8 years, SD=9.1) who had minimal or no response to antipsychotic treatment throughout 6 weeks of treatment and were not given clozapine for various reasons. Written informed consent was obtained in all cases. All patients were taking the maximum tolerated dose of the respective antipsychotic drug with sufficient plasma levels (initial treatment: one taking olanzapine, 20 mg/day; one, amisulpride, 600 mg/day; four, quetiapine 500–900 mg/day). They were monitored with use of the Brief Psychiatric Rating Scale (BPRS). Oxcarbazepine was added to antipsychotic treatment, starting with 300 mg/day and ending with a final dose of 900 to 2100 mg/day (mean=1500 mg/day, SD=465), with a transient headache as a side effect in a single case.
BPRS scores were decreased significantly from baseline (mean=58.7, SD=12.8) after 42 days of adjuvant treatment (mean=36.3, SD=9.2) (p=0.007, Student’s t test).
Despite their limitations, these data raise preliminary evidence for the adjuvant effects of oxcarbazepine in the acute treatment of schizophrenia. There is no relevant pharmacokinetic interaction between olanzapine, amisulpride, or quetiapine and oxcarbazepine (3, 4). Thus, the clinical synergism is most likely due to pharmacodynamic effects. The good tolerability of oxcarbazepine may have benefit in both treatment-resistant and acutely ill patients with slow treatment response.

References

1.
Weiden P, Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57(suppl 11):53–60
2.
Dose M, Apelt S, Emrich HM: Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987; 22:303–310
3.
Natsch S, Hekster YA, Keyser A, Deckers CLP, Meinardi H, Renier WO: Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997; 17:228–240
4.
Keck PE Jr, McElroy SL: Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63(suppl 4):3–11

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1130-a - 1131

History

Published online: 1 June 2004
Published in print: June 2004

Authors

Affiliations

F. MARKUS LEWEKE, M.D.
CHRISTOPH W. GERTH, M.D.
JOHANNES FAULHABER, M.D.
JOACHIM KLOSTERKÖTTER, M.D.
Cologne, Germany

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share